GALT logo

Galectin Therapeutics Inc.

GALT

GALT: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

more

Show GALT Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of GALT by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by GALT's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Methods for treatment of arthritis Aug. 16, 2022
  • Patent Title: Composition of novel carbohydrate drug for treatment of human diseases Oct. 13, 2020
  • Patent Title: Galactose-pronged polysaccharides in a formulation for antifibrotic therapies Aug. 18, 2020
  • Patent Title: Composition of novel carbohydrate drug for treatment of human diseases Sep. 24, 2019
  • Patent Title: Method for enhancing specific immunotherapies in cancer treatment Sep. 03, 2019
  • Patent Title: Composition of novel carbohydrate drug for treatment of human diseases May. 22, 2018
  • Patent Title: Method for treatment of pulmonary fibrosis May. 15, 2018
  • Patent Title: Method for enhancing specific immunotherapies in cancer treatment Jan. 23, 2018
  • Patent Title: Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase Sep. 19, 2017
  • Patent Title: Composition of novel carbohydrate drug for treatment of human diseases May. 16, 2017
  • Patent Title: Method for treatment of pulmonary fibrosis May. 17, 2016
  • Patent Title: Galactose-pronged polysaccharides in a formulation for antifibrotic therapies Dec. 01, 2015
  • Patent Title: Composition of novel carbohydrate drug for treatment of human diseases Feb. 24, 2015
  • Patent Title: Compositions of novel carbohydrate drug for treatment of human diseases Oct. 28, 2014
  • Patent Title: Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders Sep. 09, 2014
  • Patent Title: Galactose-pronged polysaccharides in a formulation for antifibrotic therapies May. 13, 2014
  • Patent Title: Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease Feb. 25, 2014
  • Patent Title: Galactose-pronged polysaccharides in a formulation for antifibrotic therapies Feb. 05, 2013
  • Patent Title: Galactose—pronged polysaccharides in a formulation for antifibrotic therapies Aug. 07, 2012
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of GALT in WallStreetBets Daily Discussion

GALT News

Recent insights relating to GALT

CNBC Recommendations

Recent picks made for GALT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in GALT

Corporate Flights

Flights by private jets registered to GALT